Ryvu Therapeutics (LTS:0RKT) Other Current Liabilities: zł36.72 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKT Ryvu Therapeutics SA LTS:0RKT
66 GF Score
Price zł30.25
GF Value zł93.11
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Other Current Liabilities?

Ryvu Therapeutics LTS:0RKT 66 Other Current Liabilities is zł36.72 Mil as of Mar. 2026. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł93.11. The stock has 3 warning signs investors should review.

Ryvu Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was zł36.72 Mil.

Ryvu Therapeutics's quarterly other current liabilities declined from Sep. 2025 (zł49.61 Mil) to Dec. 2025 (zł43.45 Mil) and declined from Dec. 2025 (zł43.45 Mil) to Mar. 2026 (zł36.72 Mil).

Ryvu Therapeutics's annual other current liabilities increased from Dec. 2023 (zł44.06 Mil) to Dec. 2024 (zł73.76 Mil) but then declined from Dec. 2024 (zł73.76 Mil) to Dec. 2025 (zł43.45 Mil).

Ryvu Therapeutics Other Current Liabilities Related Terms

Ryvu Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Other Current Liabilities Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.08 27.41 44.06 73.76 43.45

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.34 46.95 49.61 43.45 36.72
LTS:0RKT
66GF Score
Ryvu Therapeutics SA LTS:0RKT
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of zł36.72 Mil mean?
Ryvu Therapeutics (LTS:0RKT) has a Other Current Liabilities of zł36.72 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ryvu Therapeutics.
Is Ryvu Therapeutics' Other Current Liabilities too high?
Ryvu Therapeutics' current Other Current Liabilities is zł36.72 Mil. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Other Current Liabilities compare to VRTX and REGN?
Ryvu Therapeutics' Other Current Liabilities of zł36.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ryvu Therapeutics. Ryvu Therapeutics's current Other Current Liabilities is zł36.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Other Current Liabilities of zł36.72 Mil. The stock's GF Value™ is zł93.11, compared to a current price of zł30.25 — trading 67.5% below its estimated fair value. The current Other Current Liabilities is zł36.72 Mil. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Other Current Liabilities is zł36.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł30.25 is trading 67.5% below its estimated GF Value™ of zł93.11.

Key valuation signals for LTS:0RKT:

  • Other Current Liabilities: zł36.72 Mil
  • GF Value™: zł93.11 vs. price of zł30.25 (67.5% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for LTS:0RKT

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.25
Price
zł93.11
GF Value